A person passes a sign that reads, “The vaccine is our best shot against COVID-19” on the Upper West Side, amid the coronavirus pandemic, on March 30, 2021, in New York City.
Noam Galai | Getty Images
Johnson & Johnson privately asked rivals Pfizer and Moderna to join a study to look at the potential risk of blood clots, but the companies refused, The Wall Street Journal reported Friday, citing people familiar with the issue.
Pfizer and Moderna executives said their vaccines seemed safe and saw no need to duplicate the efforts of regulators and companies already looking at the rare issue of blood clots, according to the Journal report.
Only AstraZeneca, whose vaccine has raised concerns about blood clots by regulators, agreed to join the effort, the Journal said.
CNBC contacted the four companies for comment.
On Tuesday, the Food and Drug Administration and the Centers for Disease Control and Prevention advised states to temporarily discontinue the use of the J&J vaccine “as a precaution,” after six women developed a rare but disabling blood clotting disorder. it could be life threatening. he left one dead and one in critical condition.
The women developed the condition known as cerebral venous sinus thrombosis or CVST, about two weeks after receiving the shot, US health officials told reporters. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. Eventually it can leak into the brain tissue and cause bleeding.
A CDC group decided on Wednesday to postpone a decision on the use of the J&J vaccine while officials investigate the cases.
Read the full Wall Street Journal report here.